SNCG (Gamma-Synuclein), also known as synoretin or BCSG1 (Breast Cancer-Specific Gene 1), is a member of the synuclein family of proteins that includes alpha-synuclein (SNCA) and beta-synuclein (SNCB). Unlike its well-studied family member alpha-synuclein, SNCG is not known to form Lewy bodies in Parkinson's disease but has been extensively implicated in various cancers and exhibits neuroprotective properties[@jensen1999][@bruening2000]. The protein is primarily expressed in the peripheral nervous system, autonomic ganglia, and specific brain regions including the substantia nigra, hippocampus, and cortex[@ji1997].
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2">Gamma-Synuclein (SNCG)</th></tr>
<tr><td>Protein Name</td><td>Gamma-Synuclein</td></tr>
<tr><td>Gene</td><td>[SNCG](/genes/sncg)</td></tr>
<tr><td>UniProt</td><td>[P37840](https://www.uniprot.org/uniprot/P37840)</td></tr>
<tr><td>Location</td><td>Cytoplasm, membrane, nucleus</td></tr>
<tr><td>Function</td><td>Chaperone, neuroprotection, signaling</td></tr>
<tr><td>MW</td><td>13.0 kDa</td></tr>
<tr><td>Pathology</td><td>Cancer progression, neuroprotection</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>
SNCG shares the conserved alpha-synuclein family structure with characteristic domains[@uversky2002]:
SNCG (Gamma-Synuclein), also known as synoretin or BCSG1 (Breast Cancer-Specific Gene 1), is a member of the synuclein family of proteins that includes alpha-synuclein (SNCA) and beta-synuclein (SNCB). Unlike its well-studied family member alpha-synuclein, SNCG is not known to form Lewy bodies in Parkinson's disease but has been extensively implicated in various cancers and exhibits neuroprotective properties[@jensen1999][@bruening2000]. The protein is primarily expressed in the peripheral nervous system, autonomic ganglia, and specific brain regions including the substantia nigra, hippocampus, and cortex[@ji1997].
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2">Gamma-Synuclein (SNCG)</th></tr>
<tr><td>Protein Name</td><td>Gamma-Synuclein</td></tr>
<tr><td>Gene</td><td>[SNCG](/genes/sncg)</td></tr>
<tr><td>UniProt</td><td>[P37840](https://www.uniprot.org/uniprot/P37840)</td></tr>
<tr><td>Location</td><td>Cytoplasm, membrane, nucleus</td></tr>
<tr><td>Function</td><td>Chaperone, neuroprotection, signaling</td></tr>
<tr><td>MW</td><td>13.0 kDa</td></tr>
<tr><td>Pathology</td><td>Cancer progression, neuroprotection</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>
SNCG shares the conserved alpha-synuclein family structure with characteristic domains[@uversky2002]:
SNCG exhibits multiple neuroprotective properties that are only beginning to be fully understood[@sung2005][@ninkina2003]:
Chaperone Activity: Like other synucleins, SNCG possesses molecular chaperone activity that can prevent protein aggregation. It may help mitigate the toxic effects of misfolded proteins including alpha-synuclein and mutant huntingtin[@snyder2002].
Anti-apoptotic Effects: Studies demonstrate that SNCG can protect neurons from various apoptotic stimuli. This protection involves modulation of the Bcl-2 family proteins and caspase pathways[@katherine2005].
Mitochondrial Protection: SNCG localizes to mitochondria under stress conditions and may help maintain mitochondrial membrane potential and prevent mitochondrial permeability transition[@li2007].
Oxidative Stress Mitigation: The protein can scavenge reactive oxygen species (ROS) and protect against oxidative damage. This is particularly relevant given the role of oxidative stress in neurodegeneration[@zhang2008].
While alpha-synuclein is well-known for its role at the synaptic terminal, SNCG also participates in synaptic function[@murphy2000]:
SNCG was originally identified as BCSG1 (Breast Cancer-Specific Gene 1) due to its overexpression in breast cancer[@ji1997a]. Its expression pattern in cancer includes:
Overexpression in Multiple Cancers: High SNCG expression is found in breast, ovarian, prostate, glioma, and pancreatic cancers[@liu2012].
Metastatic Promotion: SNCG promotes cell migration and invasion in various cancer types through activation of matrix metalloproteinases (MMPs)[@sutton2013].
Signaling Pathways: In cancer cells, SNCG activates multiple pro-survival pathways including PI3K/Akt, MAPK/ERK, and NF-κB[@yan2011].
Although not a primary component of Lewy bodies, SNCG has complex relationships with PD pathophysiology[@stefanova2005][@takahashi2007]:
Modulation of Alpha-Synuclein Aggregation: SNCG can interact with alpha-synuclein and either promote or inhibit its aggregation depending on conditions. Studies show that SNCG may slow alpha-synuclein fibrillization in vitro[@uversky2001].
Compensation for Alpha-Synuclein Loss: In alpha-synuclein knockout mice, SNCG expression increases in the substantia nigra, suggesting a compensatory neuroprotective response[@takao2002].
Protection of Dopaminergic Neurons: Overexpression of SNCG protects dopaminergic neurons in models of PD, potentially through antioxidant and anti-apoptotic mechanisms[@kholodilov2004].
Genetic Findings: While SNCA mutations cause familial PD, no disease-causing mutations have been identified in SNCG. However, SNCG polymorphisms have been associated with PD susceptibility in some populations[@liu2012a].
In Alzheimer's disease, SNCG exhibits complex interactions with both amyloid and tau pathology[@galvin2000][@biere2000]:
Interaction with Tau Pathology: SNCG can bind to tau protein and may influence its phosphorylation and aggregation. Some studies find SNCG colocalization with neurofibrillary tangles[@trojanowski2001].
Modulation of Amyloid Effects: Evidence suggests SNCG may modulate the effects of amyloid-beta on synaptic function, though results are conflicting[@matsuzaki2005].
Synaptic Function: SNCG is present at synapses and may play roles in synaptic plasticity. Changes in SNCG expression are observed in AD brains[@hashimoto2001].
Multiple System Atrophy (MSA): Unlike PD, SCA immunoreactivity has been reported in some MSA cases, particularly in oligodendrocytes[@wenning2008].
Amyotrophic Lateral Sclerosis (ALS): Altered SNCG expression has been observed in ALS models and patients, though its role remains unclear[@bellingham2012].
Huntington's Disease: Studies suggest SNCG may protect against mutant huntingtin toxicity through chaperone mechanisms[@zainelli2004].
SNCG was first characterized as a breast cancer-specific gene (BCSG1)[@mahajan2009]:
Similar overexpression patterns are observed in ovarian cancer[@wang2010]:
SNCG expression in prostate cancer correlates with disease progression[@liu2011]:
In gliomas, SNCG shows oncogenic properties[@sotgia2012]:
Given its neuroprotective properties, SNCG-based therapies are being explored[@beller2010]:
Protein-Based Therapy: Recombinant SNCG or derived peptides may protect neurons from various insults[@kwon2011].
Gene Therapy: Viral vector delivery of SNCG is being investigated in PD models[@yang2013].
Small Molecule Modulators: Compounds that enhance endogenous SNCG expression represent a therapeutic approach[@chen2012].
SNCG as a target offers several opportunities[@han2013]:
Immunotherapy: Antibodies against SNCG are being developed for targeted cancer therapy[@diedrich2011].
Antisense Oligonucleotides: ASOs targeting SNCG show promise in cancer models[@kim2012].
Small Molecule Inhibitors: Development of compounds that block SNCG signaling is ongoing[@chen2013].
SNCG has been investigated as a diagnostic and prognostic biomarker[@zhang2009]:
Less clear utility in neurodegeneration:
SNCG knockout mice are viable and show subtle phenotypes[@ninkina2002]:
SNCG overexpression models demonstrate[@kholodilov2002]:
SNCG interacts with multiple cellular proteins[@lee2006]:
| Interactor | Function | Relevance |
|------------|----------|-----------|
| Alpha-synuclein | Aggregation modulation | PD |
| Synphilin-1 | Synaptic function | PD |
| 14-3-3 proteins | Signaling | Multiple |
| Hsp70 | Chaperone | Stress response |
| Bcl-2 | Anti-apoptosis | Neuroprotection |
In cancer cells, SNCG activates several pathways[@xie2010]: